LONDON--(BUSINESS WIRE)--The global castration-resistant prostate cancer (CRPC) treatment market is expected to grow at a CAGR of more than 9% during the forecast period, according to Technavio’s ...
Several novel therapies for castration-resistant prostate cancer (CRPC) have been approved with randomized phase III studies with continuing observational research either planned or ongoing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results